2022
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022, 45: 965-974. PMID: 35120199, PMCID: PMC9016734, DOI: 10.2337/dc21-1765.Peer-Reviewed Original ResearchMeSH KeywordsCanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2FemaleHeart Disease Risk FactorsHumansMaleRisk FactorsConceptsCanagliflozin Cardiovascular Assessment StudyMajor adverse cardiovascular eventsType 2 diabetesHazard ratioSodium-glucose cotransporter 2 inhibitorsCardiovascular disease benefitAdverse cardiovascular eventsCotransporter 2 inhibitorsEffects of canagliflozinCanagliflozin dosesCanagliflozin's effectsCardiovascular eventsCardiovascular riskPatients 5Cardioprotective effectsSGLT2 inhibitorsDisease benefitBaseline variablesOriginal trialCanagliflozinType 2DiabetesPatientsRisk estimatesEffect estimates
2021
Effects of canagliflozin on human myocardial redox signalling: clinical implications
Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C. Effects of canagliflozin on human myocardial redox signalling: clinical implications. European Heart Journal 2021, 42: 4947-4960. PMID: 34293101, PMCID: PMC8691807, DOI: 10.1093/eurheartj/ehab420.Peer-Reviewed Original ResearchMeSH KeywordsCanagliflozinHumansMyocardiumMyocytes, CardiacOxidation-ReductionSodium-Glucose Transporter 2 InhibitorsConceptsNADPH oxidase activityMyocardial redoxHuman cardiomyocytesNOS couplingAtrial tissueSodium-glucose cotransporter 2 inhibitorsMyocardial NADPH oxidase activityRight atrial appendage biopsiesNitric oxide synthase uncouplingCotransporter 2 inhibitorsEffects of canagliflozinHeart failure patientsBeneficial cardiac effectsExpression of inflammationRecent clinical trialsAMP kinaseHuman atrial tissueOxidase activityPrimary human cardiomyocytesAnti-apoptotic effectsTetrahydrobiopterin bioavailabilityCardiovascular outcomesCardiac effectsFailure patientsCardiac surgery